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Preeclampsia and hyperemesis gravidarum are pregnancy complications associated with altered sex hormone levels. Previous
studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and hyperemesis with an
increased risk, but the evidence remains unclear. We used data from the Generations Study, a large prospective study of
women in the United Kingdom, to estimate relative risks of breast cancer in relation to a history of preeclampsia and hyper-
emesis using Cox regression adjusting for known breast cancer risk factors. During 7.5 years average follow-up of 82,053 par-
ous women, 1,969 were diagnosed with invasive or in situ breast cancer. Women who had experienced preeclampsia during
pregnancy had a significantly decreased risk of premenopausal breast cancer (hazard ratio (HR) 50.67, 95% confidence inter-
val (CI): 0.49–0.90) and of HER2-enriched tumours (HR50.33, 95% CI: 0.12–0.91), but there was no association with overall
(HR50.90, 95% CI: 0.80–1.02) or postmenopausal (HR50.97, 95% CI: 0.85–1.12) breast cancer risk. Risk reductions among
premenopausal women were strongest within 20 years since the last pregnancy with preeclampsia. Hyperemesis was associ-
ated with a significantly increased risk of HER2-enriched tumours (HR51.76, 95% CI: 1.07–2.87), but not with other intrinsic
subtypes or breast cancer risk overall. These results provide evidence that preeclampsia is associated with a decreased risk
of premenopausal and HER2-enriched breast cancer and that hyperemesis, although not associated with breast cancer risk
overall, may be associated with raised risk of HER2-enriched tumours.
Introduction
Breast cancer is the most common type of cancer among
females worldwide and has a hormonal aetiology. During
pregnancy, breast tissue is exposed to hormonal surges
including of oestrogen and progesterone, which may be
related to the transient increased risk of breast cancer after
pregnancy, followed by a decreased risk long-term.1,2 Disor-
ders that affect hormone levels in pregnancy might therefore
also affect subsequent breast cancer risk.
Preeclampsia is a disorder characterised by the onset of
hypertension and proteinuria in the second half of preg-
nancy, affecting around 2–8% of pregnancies,3 which is asso-
ciated with decreased levels of estradiol4 and insulin-like
growth factors.5,6 It has been hypothesised that preeclampsia
might therefore be associated with a decreased risk of mater-
nal breast cancer.7 Evidence from previous studies has been
inconsistent, however, with studies reporting negative,7–11
positive12 or no13–17 association with breast cancer risk. Few
studies have been of prospective design and the studies have
often not been able to adjust for potential confounders. Only
a few studies have reported on whether the association
depends on age at birth,9,18 number of preeclamptic pregnan-
cies,10 sex of offspring,8,18 menopausal status10 or
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invasiveness of breast cancer13 and none have investigated
the association by breast cancer intrinsic subtype.
Hyperemesis gravidarum (hereafter referred to as ‘hyper-
emesis’) is characterised by severe nausea, vomiting and
faintness in the ﬁrst half of pregnancy. It has been hypothes-
ised that it could be associated with a raised risk of maternal
breast cancer via elevated estradiol levels in pregnancy.19 The
few past studies have not consistently shown an association
of hyperemesis with breast cancer risk,13,14,20–24 but all except
one13 have been of case–control design, which could be
prone to recall bias.
We therefore examined the association between history of
preeclampsia and hyperemesis and maternal risk of breast
cancer in women within the Generations Study, a large pro-
spective cohort study in the UK, in which detailed informa-
tion on pregnancies, breast cancer risk factors and breast
cancer characteristics was available.
Materials and Methods
The Generations Study is a cohort study of over 113,700
women from the United Kingdom (UK), aged 16 years or
older, designed to investigate the aetiology of breast cancer.
Questionnaire information and informed consent were gained
at recruitment since 2003. The ﬁrst follow-up questionnaire
(21=2 years after recruitment) was completed by 99% of non-
deceased participants, the second (6 years after recruitment)
by 96%, and the third (91=2 years after recruitment) by 94%
of those recruited long enough ago to have entered this
round of follow-up. The study was approved by the South
East Multi-Centre Research Ethics Committee and has been
described in detail previously.25
Breast cancers occurring in the cohort were identiﬁed from
recruitment and follow-up questionnaires and spontaneous
reports to the study centre, and where necessary from ‘ﬂagging’
at the National Health Service Central Registers (virtually com-
plete register of the populations of England, Wales and Scot-
land, to which study participants can be linked and on which
deaths and cancer registrations are ‘ﬂagged’ and then reported
to authorised medical researchers). Conﬁrmation of diagnosis
was obtained from UK cancer registries, pathology reports and
correspondence with patients’ general practitioners.
Information on pregnancies was collected in the recruitment
and second follow-up questionnaires. Participants were asked if
they had experienced preeclampsia or hyperemesis gravidarum
(i.e., severe vomiting every day for at least a week in the ﬁrst 3
months of pregnancy), and about birth outcome, gestational
length, offspring sex and birth weight at each of their pregnan-
cies. Age at ﬁrst and last pregnancy and time since last preg-
nancy with preeclampsia and hyperemesis were calculated using
information from individual pregnancies.
Information on menopausal status and age at menopause
was obtained from the recruitment and second follow-up
questionnaires, in which women were asked how old they
were when their periods stopped completely (i.e., they had
gone 6 months without having had a period). For women
who did not provide an age at menopause but who reported
that they became postmenopausal during follow-up, we
deﬁned menopausal age to be the youngest of either the
woman’s age at the questionnaire at which she ﬁrst reported
that she was postmenopausal or age 50.
Statistical analysis
The analytic cohort in our study is based on all women who
were recruited to the Generations Study before 31 December
2013, did not have a previous diagnosis of invasive or in situ
breast cancer, and were either parous (deﬁned as pregnancies
of 26 weeks resulting in a live birth) at recruitment or
became parous during follow-up. The recruitment cut-off at
December 2013 was selected because at the time of analysis
the second follow-up was virtually complete, two-thirds had
reached the third follow-up, and we had ‘ﬂagging’ informa-
tion to June 2017 for these recruits. Participants entered risk
at the date of return of their recruitment questionnaire, or if
they were nulliparous at recruitment and became parous dur-
ing follow-up, the date of ﬁrst delivery, and were censored at
the earliest of: ﬁrst invasive or in situ breast cancer; death;
most recent follow-up questionnaire (depending on date of
recruitment), if completed, or the date the most recent
follow-up questionnaire was due if cancer and vital status
was known from ‘ﬂagging’; or the date of the last completed
questionnaire, if lost to study follow-up. We additionally cen-
sored at the ﬁrst age of having a twin or higher-order birth,
since such births are associated with higher hormone expo-
sures.26 Cox proportional hazards regression27 using attained
age as the implicit time scale was used to estimate hazard
ratios (HR) and 95% conﬁdence intervals (CI) for risk of ﬁrst
breast cancer in relation to pregnancy complications. Models
were adjusted for: socio-economic score;28 birth cohort;
What’s new?
Although the link of preeclampsia and hyperemesis gravidarum with altered sex hormone levels is well established, relatively
little is known about the association of these pregnancy complications with breast cancer risk. Here, the authors found that a
history of preeclampsia decreased the risk of premenopausal breast cancer and tumors enriched for the receptor tyrosine-
protein kinase HER2. In contrast, hyperemesis gravidarum increased the risk to develop HER2-enriched tumors, pointing to
nuanced differences of sex hormone alterations during pregnancy with respect to breast cancer subtypes and menopausal
status.
C
an
ce
r
E
p
id
em
io
lo
g
y
2 Prospective analysis in the generations study
Int. J. Cancer: 00, 00–00 (2018) VC 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
benign breast disease; family history of breast cancer in 1st
degree relatives; age at menarche; parity; age at ﬁrst birth;
number of parous births; duration of breastfeeding across all
births; body mass index (BMI) at age 20 years; postmeno-
pausal BMI, if applicable; height at recruitment; premeno-
pausal oral contraceptive use; menopausal status; age at
menopause; hormone replacement therapy use; alcohol con-
sumption; cigarette smoking status and physical activity level.
The baseline reference group for pregnancy complication vari-
ables was comprised of parous women with no history of pre-
eclampsia, or of hyperemesis, depending on the risk factor
under analysis. Pregnancy and complications of pregnancy
data were analysed as time-dependent variables, such that
women were considered as having no history of preeclampsia
before a pregnancy with the condition, and then contributed
to the preeclampsia risk group from that pregnancy onwards.
HRs were estimated for breast cancer overall and subdivided
by time-updated menopausal status, oestrogen receptor (ER)
status, invasiveness and intrinsic subtype of breast cancer.
Breast cancer intrinsic subtype deﬁnitions were adapted from
those proposed by the St Gallen Expert Consensus.29 To assess
the trends in risk across number of pregnancies and time since
last pregnancy with complications we modelled continuous
variables, excluding women with zero pregnancies. Likelihood
ratio tests30 were used to test for interactions between pre-
eclampsia variables and the subjects’ mother’s history of pre-
eclampsia, sex of the offspring at ﬁrst and last pregnancy with
preeclampsia, and between history of preeclampsia and history
of hyperemesis. All statistical tests were two-sided and analyses
were conducted using Stata/IC version 14.2.31
Results
During 2003–2013 the recruitment questionnaire was com-
pleted by 106,628 study participants who had no previous
invasive or in situ breast cancer, or prophylactic mastectomy.
Women who remained nulliparous throughout follow-up
(n5 22,359) and women who had a twin or higher-order
birth before entry to the study (n5 2,216) were excluded
from the analysis. The analytical cohort included 82,053
women who were either parous at baseline questionnaire
(n5 78,539) or became parous during follow-up (n5 3,514)
and therefore entered follow-up at their ﬁrst parous birth.
Three hundred and twenty nine women were censored at
their ﬁrst twin or higher-order birth during follow-up. Dur-
ing follow-up, 1.2% of women died. Of the remainder, cancer
and vital status was known for 97.4% from completion of the
relevant follow-up questionnaire, and a further 2.4% from
‘ﬂagging’ at the National Health Service Central Registers.
The remaining 0.2% were lost to follow-up at an earlier date.
The follow-up completeness (calculated as the total observed
person-years divided by the maximum person-years that
would have been achievable if all women were followed-up to
their relevant questionnaire or, if earlier, death) was 99.7%.
There were 1,969 incident breast cancers during follow-up
(1,665 invasive, 304 in situ), of which 99.6% were conﬁrmed
through national cancer registration or medical records and
the remaining eight cases were self-reported with treatments
that implied breast cancer. ER information was available for
91.2% of breast cancers (99.3% of invasive, 47.0% of in situ),
and of these 83% were ER positive.
The median age at recruitment was 49.0 years (inter-quar-
tile range: 39–58) and participants contributed an average of
7.5 years of follow-up. Characteristics of the participants
overall and by preeclampsia and hyperemesis history are
given in Table 128. In the analytical cohort, 99% of women
self-reported as Caucasian, 14.8% reported that they had
experienced preeclampsia during at least one of their full-
term pregnancies, whilst 28.7% reported hyperemesis.
Preeclampsia
Women who reported a history of preeclampsia during a
pregnancy had a similar risk of breast cancer overall com-
pared to parous women who had never experienced pre-
eclampsia (HR5 0.90, 95% CI: 0.80–1.02) (Table 2). Risk of
breast cancer was signiﬁcantly decreased during the 20 years
after preeclampsia (HR5 0.75, 95% CI: 0.60–0.93), but 20 or
more years after experiencing it, women had a similar risk to
those who had never had preeclampsia. Risk was similarly
reduced for preeclampsia at ﬁrst pregnancy (HR5 0.86, 95%
CI: 0.75–0.99) and most recent (hereafter referred to as ‘last’)
pregnancy (HR5 0.88, 95% CI: 0.75–1.04). For premeno-
pausal breast cancer a signiﬁcant reduction in risk after pre-
eclampsia was observed (HR5 0.67, 95% CI: 0.49–0.90) and
in women with a history of one preeclamptic pregnancy
(HR5 0.68, 95% CI: 0.49–0.95), but with no signiﬁcant trend
(ptrend5 0.29) across the number of pregnancies with pre-
eclampsia. Risk reductions for premenopausal women were
signiﬁcant for women whose ﬁrst preeclamptic pregnancy
was at ages 25 or over (HR5 0.61, 95% CI: 0.43–0.86), or
whose last preeclamptic pregnancy was at ages under 30
years (HR5 0.60, 95% CI: 0.39–0.92), or during the 20 years
after the last preeclamptic pregnancy (HR5 0.64, 95% CI:
0.47–0.88). The risk of premenopausal breast cancer was also
signiﬁcantly reduced for preeclampsia experienced at a ﬁrst
(HR5 0.70, 95% CI: 0.51–0.97) or a last pregnancy
(HR5 0.49, 95% CI: 0.31–0.79). The relative risk of premen-
opausal breast cancer in relation to a history of preeclampsia
remained signiﬁcantly decreased when the analyses were
restricted to invasive breast tumours only (Supporting Infor-
mation Table S1). For postmenopausal breast cancer, there
was no signiﬁcant association of risk with any of the above
preeclampsia variables.
Relative risks with respect to preeclampsia were similar
for ER positive and ER negative tumours (Table 3). Risk of
ER positive breast cancer was signiﬁcantly reduced within 20
years of the last preeclamptic pregnancy (HR5 0.76; 95% CI:
0.59–0.98), but not signiﬁcantly associated with other varia-
bles. When analysed by invasiveness of breast cancer, risk
reductions for invasive cancer were in general slightly greater
than for breast cancer overall, with similar relative risks for
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Table 1. Characteristics of the analytical cohort
Characteristic
All Ever preeclampsia1
Ever hyperemesis
gravidarum1
N subjects % N subjects % N subjects %
Age at start of follow-up, years
<30 3,519 4.3 316 2.6 923 3.9
30–39 18,282 22.3 1,874 15.4 4,013 17.1
40–49 19,688 24.0 2,842 23.4 5,235 22.3
50 40,564 49.4 7,104 58.5 13,345 56.7
Number of births
1 20,140 24.5 2,166 17.8 3,992 17.0
2 41,925 51.1 6,522 53.7 12,643 53.8
3 19,988 24.4 3,448 28.4 6,881 29.3
Age at first birth, years
24 25,519 31.1 4,540 37.4 10,527 44.8
25–34 50,395 61.4 6,946 57.2 12,190 51.8
35 6,124 7.5 648 5.3 795 3.4
Parous, unknown age 15 0.02 3 0.02 4 0.02
Preeclampsia
Never 69,917 85.2 – – 19,183 81.6
Ever 12,136 14.8 12,136 100.0 4,333 18.4
Number of pregnancies with preeclampsia
1 8,686 71.6 8,686 71.6 2,915 12.4
2 2,756 22.7 2,756 22.7 1,105 4.7
3 694 5.7 694 5.7 313 1.3
Hyperemesis gravidarum
Never 58,537 71.3 7,803 64.3 – –
Ever 23,516 28.7 4,333 35.7 23,516 100.0
Number of pregnancies with hyperemesis
1 10,532 44.8 1,816 15.0 10,532 44.8
2 9,068 38.6 1,744 14.4 9,068 38.6
3 3,916 16.7 773 6.4 3,916 16.7
Menopausal status at start of follow-up
Premenopausal 42,113 51.3 5,114 42.1 10,180 43.3
Postmenopausal 35,636 43.4 6,263 51.6 11,909 50.6
Unknown 4,304 5.2 759 6.3 1,427 6.1
First-degree family history of breast cancer at recruitment
No 69,092 84.2 10,205 84.1 19,604 83.4
Yes 12,961 15.8 1,931 15.9 3,912 16.6
BMI at recruitment, units (kg/m2)
<20 4,551 5.5 378 3.1 978 4.2
20–24.9 39,008 47.5 4,476 36.9 9,855 41.9
25 35,625 43.4 6,937 57.2 11,953 50.8
Unknown 2,869 3.5 345 2.8 730 3.1
Socio-economic status based on place of residence at recruitment2
1 (highest) 39,603 48.3 5,919 48.8 11,221 47.7
2 7,718 9.4 858 7.1 1,643 7.0
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Table 1. Characteristics of the analytical cohort (Continued)
Characteristic
All Ever preeclampsia1
Ever hyperemesis
gravidarum1
N subjects % N subjects % N subjects %
3 23,198 28.3 3,527 29.1 6,851 29.1
4 6,314 7.7 1,023 8.4 1,998 8.5
5 (lowest) 4,581 5.6 732 6.0 1,630 6.9
No classification 6393 0.8 77 0.6 173 0.7
Total subjects 82,053 100.0 12,136 100.0 23,516 100.0
1Self-reported history of preeclampsia and hyperemesis gravidarum.
2Based on ACORN definitions of place of residence.28
3No classification for 414 because they were resident in the Channel Islands for which ACORN coding is not available; and for 225 for other reasons
e.g. resident in an institution.
Table 2. Relative risk of breast cancer in relation to history of preeclampsia, by menopausal status
Risk factor
Menopausal status of subject at breast cancer incidence
Overall breast cancer Premenopausal Postmenopausal
N cases Adjusted HR1 (95% CI) N cases Adjusted HR2 (95% CI) N cases Adjusted HR1 (95% CI)
Never/ever preeclampsia
Never 1,673 1.00 (ref) 480 1.00 (ref) 1,193 1.00 (ref)
Ever 294 0.90 (0.80–1.02) 48 0.67 (0.49–0.90) 246 0.97 (0.85–1.12)
Number of pregnancies with preeclampsia*
1 212 0.94 (0.82–1.09) 37 0.68 (0.49–0.95) 175 1.03 (0.88–1.20)
2 64 0.79 (0.61–1.01) 11 0.74 (0.41–1.35) 53 0.81 (0.61–1.06)
3 18 0.91 (0.57–1.46) 0 – 18 1.08 (0.68–1.74)
p trend3 0.22 0.29 0.38
Age at first preeclamptic pregnancy, years*
<25 85 0.86 (0.68–1.08) 12 0.83 (0.45–1.51) 73 0.86 (0.67–1.11)
25 208 0.92 (0.79–1.06) 35 0.61 (0.43–0.86) 173 1.03 (0.87–1.21)
Age at most recent preeclamptic pregnancy, years*
<30 174 0.86 (0.73–1.01) 22 0.60 (0.39–0.92) 152 0.92 (0.78–1.09)
30 119 0.96 (0.80–1.16) 25 0.71 (0.47–1.06) 94 1.07 (0.87–1.33)
Time since most recent preeclamptic pregnancy, years*
<20 83 0.75 (0.60–0.93) 43 0.64 (0.47–0.88) 40 0.90 (0.65–1.24)
20 211 0.98 (0.85–1.14) 5 0.95 (0.38–2.35) 206 0.99 (0.85–1.15)
p trend4 0.99 0.44 0.81
Preeclampsia at first pregnancy
No 1,738 1.00 (ref) 486 1.00 (ref) 1,252 1.00 (ref)
Yes 229 0.86 (0.75–0.99) 42 0.70 (0.51–0.97) 187 0.91 (0.78–1.06)
Preeclampsia at last pregnancy
No 1,812 1.00 (ref) 510 1.00 (ref) 1,302 1.00 (ref)
Yes 155 0.88 (0.75–1.04) 18 0.49 (0.31–0.79) 137 0.99 (0.83–1.18)
HR: hazard ratio; CI: confidence interval.
*Reference group5 never preeclampsia.
1Adjusted for attained age, socio-economic score, birth cohort, benign breast disease, family history of breast cancer, age at menarche, age at first
birth, number of births, duration of breast feeding, menopausal status, age at menopause, BMI at age 20 years, postmenopausal BMI, height, OC
use, HRT use, alcohol consumption (units/wk), cigarette smoking status, physical activity level (METs/wk).
2Same as (1) but with removal of adjustment for menopausal status, age at menopause and postmenopausal BMI.
3Test for linear trend per pregnancy with preeclampsia, excluding zero pregnancies.
4Test for linear trend per 5 years since last preeclamptic pregnancy.
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ﬁrst or last preeclamptic pregnancy at ages under 25 and 30
years respectively (HR5 0.72, 95% CI: 0.55–0.94; HR5 0.79;
95% CI: 0.66–0.95). For in situ breast cancer, however, there
was no association with ever having had preeclampsia
(HR5 1.01, 95% CI: 0.74–1.37), nor with subdivisions of
this, except for a positive association in women aged under
25 years at their ﬁrst preeclamptic pregnancy (HR5 1.62;
95% CI: 1.03–2.57). Ever having had preeclampsia was asso-
ciated with a signiﬁcantly decreased risk of human epidermal
growth factor receptor 2 (HER2)-enriched breast cancer
(HR5 0.33; 95% CI: 0.12–0.91), but there was no association
with other intrinsic subtypes (Table 4).
Relative risks with respect to preeclampsia did not vary
appreciably according to whether the subject’s mother had
experienced preeclampsia at the subject’s birth (Table 5). The
relative risk of breast cancer after preeclampsia during a ﬁrst
pregnancy was signiﬁcantly reduced in women who gave
birth to a girl (HR5 0.79; 95% CI: 0.65–0.97), but not in
those who gave birth to a boy (HR5 0.94, 95% CI: 0.78–
1.14), and no greater reduction for female than male off-
spring at the last birth, nor a signiﬁcant interaction with sex
of the offspring (pint5 0.23 and pint5 0.67). Relative risks
with respect to preeclampsia did not vary signiﬁcantly
according to whether the subject also had a history of hyper-
emesis, or vice versa (pint5 0.21) (Supporting Information
Tables S2 and S3).
Hyperemesis gravidarum
The overall risk of breast cancer in relation to ever having
experienced hyperemesis was close to unity (HR5 1.03; 95%
Table 3. Relative risk of breast cancer in relation to history of preeclampsia, by oestrogen receptor status and invasive/in situ breast cancer
Risk factor
ER status Invasive/in situ
ER positive ER negative Invasive In situ
N cases
Adjusted HR1
(95% CI) N cases
Adjusted HR1
(95% CI) N cases
Adjusted HR1
(95% CI) N cases
Adjusted HR1
(95% CI)
Never/ever preeclampsia
Never 1,266 1.00 (ref) 263 1.00 (ref) 1,419 1.00 (ref) 254 1.00 (ref)
Ever 225 0.90 (0.78–1.04) 40 0.80 (0.57–1.12) 244 0.88 (0.77–1.01) 50 1.01 (0.74–1.37)
Number of pregnancies with preeclampsia*
1 158 0.92 (0.78–1.09) 30 0.86 (0.59–1.26) 171 0.90 (0.76–1.05) 41 1.20 (0.86–1.67)
2 53 0.85 (0.64–1.12) 6 0.49 (0.22–1.11) 56 0.81 (0.62–1.06) 8 0.65 (0.32–1.33)
3 14 0.93 (0.54–1.58) 4 1.36 (0.49–3.71) 17 1.03 (0.63–1.67) 1 0.31 (0.04–2.22)
p trend2 0.45 0.74 0.63 0.06
Age at first preeclamptic pregnancy, years*
<25 60 0.81 (0.62–1.06) 14 0.82 (0.47–1.45) 61 0.72 (0.55–0.94) 24 1.62 (1.03–2.57)
25 165 0.94 (0.80–1.11) 26 0.79 (0.52–1.19) 183 0.95 (0.81–1.11) 25 0.72 (0.48–1.10)
Age at most recent preeclamptic pregnancy, years*
<30 128 0.83 (0.69–1.00) 25 0.78 (0.51–1.18) 136 0.79 (0.66–0.95) 38 1.23 (0.87–1.74)
30 97 1.02 (0.83–1.26) 15 0.83 (0.49–1.41) 108 1.03 (0.84–1.25) 11 0.59 (0.32–1.09)
Time since most recent preeclamptic pregnancy, years*
<20 63 0.76 (0.59–0.98) 12 0.66 (0.37–1.19) 67 0.72 (0.56–0.93) 16 0.87 (0.52–1.46)
20 162 0.98 (0.83–1.16) 28 0.88 (0.59–1.32) 177 0.97 (0.82–1.13) 34 1.09 (0.75–1.58)
p trend3 0.92 0.86 0.80 0.84
Preeclampsia at first pregnancy
No 1,318 1.00 (ref) 269 1.00 (ref) 1,474 1.00 (ref) 264 1.00 (ref)
Yes 173 0.85 (0.73–1.00) 34 0.84 (0.59–1.21) 189 0.84 (0.72–0.98) 40 0.99 (0.71–1.39)
Preeclampsia at last pregnancy
No 1,370 1.00 (ref) 284 1.00 (ref) 1,531 1.00 (ref) 281 1.00 (ref)
Yes 121 0.90 (0.75–1.09) 19 0.69 (0.43–1.11) 132 0.89 (0.74–1.06) 23 0.85 (0.56–1.31)
ER: oestrogen receptor; HR: hazard ratio; CI: confidence interval.
*Reference group5 never preeclampsia.
1Adjusted for attained age, socio-economic score, birth cohort, benign breast disease, family history of breast cancer, age at menarche, age at first
birth, number of births, duration of breast feeding, menopausal status, age at menopause, BMI at age 20 years, postmenopausal BMI, height, OC
use, HRT use, alcohol consumption (units/wk), cigarette smoking status, physical activity level (METs/wk).
2Test for linear trend per pregnancy with preeclampsia, excluding zero pregnancies.
3Test for linear trend per 5 years since last preeclamptic pregnancy.
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CI: 0.94–1.14) (Table 6). There was no trend of risk with
number of pregnancies with hyperemesis (ptrend5 0.44) or
time since last hyperemetic pregnancy (ptrend5 0.83), and
no association with the age at hyperemetic pregnancy or
with hyperemesis at ﬁrst or last pregnancy. Relative risks
did not vary by menopausal status at follow-up, or ER sta-
tus or invasiveness of breast cancer (Supporting Informa-
tion Table S4). Risk of HER2-enriched breast cancer was
signiﬁcantly raised in women who had experienced hyper-
emesis (HR5 1.76; 95% CI: 1.07–2.87), but there was no
association with other intrinsic subtypes of breast cancer
(Table 4).
Discussion
In this large prospective investigation, women who experi-
enced preeclampsia during a pregnancy were at signiﬁcantly
reduced risk of breast cancer at premenopausal ages and of
HER2-enriched breast cancer. Risk reductions amongst over-
all, ER positive and invasive breast cancers were observed
during the 20 years since the last pregnancy with preeclamp-
sia, with strongest reductions observed amongst premeno-
pausal women, but not in those who last experienced
preeclampsia >20 years after the pregnancy with preeclamp-
sia. We observed no signiﬁcant associations of breast cancer
risk with a history of hyperemesis except for a signiﬁcant
positive association with HER2-enriched breast cancer.
The literature on breast cancer risk in women with a his-
tory of preeclampsia is inconsistent. Some studies have
reported an inverse association,7–11 one a positive associa-
tion12 and others, including meta-analyses, reported no asso-
ciation.13–17 Only two studies, both of case–control design,
investigated the association between preeclampsia history and
breast cancer by menopausal status, with one reporting a
decreased risk of postmenopausal but not premenopausal
breast cancer10 and the other no association in either
group,14 contrary to our ﬁndings of a reduced risk of pre-
menopausal but not postmenopausal breast cancer. One
study investigated if the association may depend on age at
preeclamptic pregnancy,9 ﬁnding no association, similar to
our ﬁndings. We did not observe that the associations dif-
fered between invasive and in situ breast cancer, in accord
with the only previous study that analysed this.13 The preva-
lence of reported preeclampsia in our study (14.8%) was
higher than in clinical surveys of prevalence of this condition
(e.g., 2–8%3). It is possible that there was over-reporting by
women including gestational hypertension i.e. hypertension
in the second half of pregnancy, but without proteinuria, as
preeclampsia. This potential misclassiﬁcation is unlikely to
have affected our results since previous studies have found
the associations with breast cancer risk for gestational hyper-
tension and preeclampsia to be similar.10,32,33
Potential mechanisms for risk reductions in breast cancer
for women with a history of preeclampsia could be due to
lower levels of oestrogens4 or of growth factors such as IGF-
16 and IGF1R34 in such women, factors which have been
implicated in breast cancer risk,35,36 and lower levels of
VEGF,37 an important component in breast tumour angio-
genesis.38 Furthermore, women with preeclampsia were
reported to have a lower breast cancer susceptibility poly-
genic risk score as well as lower mammographic density,39
factors which are associated with a reduced risk of breast
cancer.40
Although there is no evidence to suggest an association
between sex of the offspring and long-term risk of breast
cancer in pregnancies without complications,41 Vatten et al.8
and Troisi et al.18 reported that breast cancer risk is modiﬁed
by offspring sex in pregnancies with preeclampsia, with
Table 4. Relative risk of breast cancer by tumour intrinsic subtype in
relation to history of preeclampsia and hyperemesis
Risk factor and intrinsic
subtype of breast cancer1
Number
of cases
Adjusted HR2
(95% CI)Ever Never
Ever had preeclampsia
Luminal A-like 91 483 0.97 (0.77–1.21)
Luminal B-like 37 246 0.80 (0.57–1.14)
Luminal B-like, HER22 18 95 0.97 (0.58–1.61)
Luminal B-like, HER21 15 127 0.66 (0.39–1.13)
Luminal, NS 96 531 0.90 (0.72–1.12)
Non-luminal 31 206 0.79 (0.54–1.15)
HER2-enriched 4 66 0.33 (0.12–0.91)
Triple negative 23 108 1.08 (0.68–1.70)
Ever had hyperemesis gravidarum
Luminal A-like 168 406 0.97 (0.80–1.17)
Luminal B-like 85 198 1.03 (0.79–1.34)
Luminal B-like, HER22 39 74 1.22 (0.82–1.82)
Luminal B-like, HER21 39 103 0.96 (0.66–1.41)
Luminal, NS 211 416 1.08 (0.91–1.28)
Non-luminal 73 164 1.06 (0.80–1.41)
HER2-enriched 28 42 1.76 (1.07–2.87)
Triple negative 40 91 1.00 (0.68–1.46)
ER: oestrogen receptor; PR: progesterone receptor; HER2: human epi-
dermal growth factor 2; 1: positive; 2: negative; ?: not known; NS:
not-specified; RR: relative risk; CI: confidence interval.
1Intrinsic subtype groups are not mutually exclusive:
Luminal A-like 5ER1 PR1HER22.
Luminal B-like5 ER1/PR1 and HER21; ER1 PR2 and HER2? ER2 PR1
and HER2?
Luminal B-like, HER225ER1 PR2 HER22; ER2 PR1HER22.
Luminal B-like, HER215 ER1/PR1 and HER21.
Luminal, NS5 ER1/PR1 and HER22; ER1/PR1 and HER2?
Non-luminal5 ER2PR2HER2?
HER2 enriched5 ER2PR2HER21.
Triple negative5 ER2PR2HER22.
2Adjusted for attained age, socio-economic score, birth cohort, benign
breast disease, family history of breast cancer, age at menarche, age
at first birth, number of births, duration of breast feeding, menopausal
status, age at menopause, BMI at age 20 years, postmenopausal BMI,
height, OC use, HRT use, alcohol consumption (units/wk), cigarette
smoking status, physical activity level (METs/wk).
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Table 5. Relative risk of breast cancer in relation to history of preeclampsia, mother’s history of preeclampsia and sex of offspring
Risk factor
Subjects’ mother had preeclampsia at subjects’ pregnancy
pint
2
Sex of offspring at subjects’ preeclampsia delivery
pint
2
Yes No Boy Girl
N cases
Adjusted HR1
(95% CI) N cases
Adjusted HR1
(95% CI) N cases
Adjusted HR1
(95% CI) N cases
Adjusted HR1
(95% CI)
Never/ever preeclampsia
Never 43 1.00 (ref) 1,260 1.00 (ref) – – – – –
Ever 20 0.85 (0.50–1.45) 182 0.93 (0.80–1.09) 0.75 – – – – –
Number of pregnancies
with preeclampsia
1 12 1.00 (ref) 136 1.00 (ref) – – – – –
2 6 0.81 (0.30–2.20) 37 0.77 (0.53–1.12) – – – – –
3 2 1.55 (0.34–7.11) 9 0.85 (0.42–1.75) 0.80 – – – – –
Preeclampsia at first
pregnancy
No 47 1.00 (ref) 1,299 1.00 (ref) 831 1.00 (ref) 904 1.00 (ref)
Yes 16 0.79 (0.45–1.39) 143 0.90 (0.76–1.07) 0.65 123 0.94 (0.78–1.14) 106 0.79 (0.65–0.97) 0.23
Preeclampsia at last
pregnancy
No 51 1.00 (ref) 1,350 1.00 (ref) 883 1.00 (ref) 925 1.00 (ref)
Yes 12 0.84 (0.45–1.57) 92 0.92 (0.74–1.13) 0.79 73 0.85 (0.67–1.08) 82 0.91 (0.73–1.15) 0.67
1Adjusted for attained age, socio-economic score, birth cohort, benign breast disease, family history of breast cancer, age at menarche, age at first birth, number of births, duration of breast feeding,
menopausal status, age at menopause, BMI at age 20 years, postmenopausal BMI, height, OC use, HRT use, alcohol consumption (units/wk), cigarette smoking status, physical activity level
(METs/wk).
2Interaction test p-values.
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strongest reductions for pregnancies involving a male foetus.
Troisi et al.18 reported higher circulating levels of androgens
during a pregnancy with preeclampsia with a male than a
female foetus. Our results did not show such a pattern: for
ﬁrst pregnancies there was a signiﬁcant reduction only for
female offspring, although not signiﬁcant heterogeneity by
sex of offspring, and for last pregnancies there was no indica-
tion of an affect by sex of offspring.
Since a maternal history of preeclampsia in the pregnancy
leading to the subject’s birth is a risk factor for experiencing
preeclampsia in the subject’s own pregnancy,42 we investi-
gated whether there was variation in breast cancer risk in
relation to preeclampsia according to whether the subject’s
mother had experienced preeclampsia during the pregnancy
from which the subject was born or not, but we found no
signiﬁcant difference between the two groups.
An adverse effect of hyperemesis on breast cancer risk has
been proposed because of reported higher estradiol levels in
pregnancies with hyperemesis.43,44 We found, however, that
women who had experienced hyperemesis during any of their
pregnancies had similar breast cancer risk overall to women
who did not, at both premenopausal and postmenopausal
ages. This is contrary to results from a case–control study
reporting a positive association after a recent hyperemetic
pregnancy in premenopausal women24 and one reporting
inverse associations,14 but accords with several other stud-
ies.13,20–23 The prevalence of reported hyperemesis in our
study (28.7%) was much higher than in surveys of prevalence
Table 6. Relative risk of breast cancer in relation to history of hyperemesis gravidarum, by menopausal status
Risk factor
Menopausal status of subject at breast cancer incidence
Overall breast cancer Premenopausal Postmenopausal
N cases Adjusted HR (95% CI)1 N cases Adjusted HR (95% CI)2 N cases Adjusted HR (95% CI)1
Never/ever hyperemesis
Never 1,350 1.00 (ref) 386 1.00 (ref) 964 1.00 (ref)
Ever 617 1.03 (0.94–1.14) 142 1.10 (0.91–1.34) 475 1.01 (0.90–1.13)
Number of pregnancies with hyperemesis*
1 240 1.00 (0.87–1.15) 64 1.14 (0.87–1.49) 176 0.96 (0.82–1.13)
2 274 1.09 (0.95–1.25) 61 1.13 (0.85–1.49) 213 1.08 (0.92–1.26)
3 103 0.96 (0.77–1.20) 17 0.91 (0.54–1.52) 86 0.97 (0.76–1.23)
p trend3 0.44 0.34 0.62
Age at first hyperemetic pregnancy, years*
<25 266 1.07 (0.91–1.26) 35 1.12 (0.74–1.70) 231 1.06 (0.90–1.26)
25 351 1.01 (0.90–1.14) 107 1.10 (0.88–1.36) 244 0.98 (0.84–1.13)
Age at most recent hyperemetic pregnancy, years*
<30 377 1.02 (0.91–1.15) 67 1.23 (0.93–1.62) 310 0.99 (0.86–1.13)
30 240 1.05 (0.91–1.20) 75 1.02 (0.79–1.30) 165 1.06 (0.90–1.26)
Time since most recent hyperemetic pregnancy, years*
<20 197 1.06 (0.90–1.24) 131 1.10 (0.90–1.34) 66 0.99 (0.76–1.29)
20 420 1.02 (0.90–1.15) 11 1.14 (0.60–2.18) 409 1.02 (0.90–1.15)
p trend4 0.83 0.80 0.56
Hyperemesis at first pregnancy
No 1,413 1.00 (ref) 403 1.00 (ref) 1,010 1.00 (ref)
Yes 554 1.04 (0.94–1.15) 125 1.14 (0.93–1.39) 429 1.01 (0.90–1.14)
Hyperemesis at last pregnancy
No 1,509 1.00 (ref) 424 1.00 (ref) 1,085 1.00 (ref)
Yes 458 1.01 (0.90–1.12) 104 1.00 (0.80–1.24) 354 1.01 (0.89–1.14)
HR: hazard ratio; CI: confidence interval.
*Reference group5 never hyperemesis.
1Adjusted for attained age, socio-economic score, birth cohort, benign breast disease, family history of breast cancer, age at menarche, age at first
birth, number of births, duration of breast feeding, menopausal status, age at menopause, BMI at age 20 years, postmenopausal BMI, height, OC
use, HRT use, alcohol consumption (units/wk), cigarette smoking status, physical activity level (METs/wk).
2Same as (1) but with removal of adjustment for postmenopausal BMI.
3Test for linear trend per pregnancy with preeclampsia, excluding zero pregnancies.
4Test for linear trend per 5 years since last hyperemetic pregnancy.
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of this condition (e.g., 0.3–3%45,46). It seems likely that there
was over-reporting by women including moderate morning
sickness as hyperemesis. If any putative effects of hyperemesis
on risk of breast cancer were restricted to full hyperemesis,
not moderate morning sickness, then our study might have
greatly underestimated any true effect. However, some studies
have shown that hormone levels rise incrementally with the
severity of nausea and vomiting,43,44 suggesting that morning
sickness lies at the lower range of a spectrum and hence a
true effect might have been reﬂected to be null to some
extent.
To our knowledge there have been no previous investiga-
tions of risk by tumour intrinsic subtypes of breast cancer in
relation to history of preeclampsia or hyperemesis. We found
that the strongest associations for both pregnancy complica-
tions were for HER2-enriched tumours. Risk of this type of
breast cancer was reduced in women with a history of pre-
eclampsia, which is associated with lower levels of estriol,4
insulin-like growth factors5,6 and plasma epidermal growth
factor levels during pregnancy,47 although our results were
based on only 4 cases. Risk of HER2-enriched breast cancer
was signiﬁcantly increased, however, in women with hyper-
emesis. The aetiology of HER2-enriched breast cancer is rela-
tively unknown, but recent studies report strong associations
with the time interval between menarche and ﬁrst birth,48
and with age at menopause.49
While there are several strengths to our study, including
its large size, prospective design, high completeness of follow-
up and quality of covariate data, we are dependent on self-
reported history of preeclampsia and hyperemesis, although
collected prior to breast cancer diagnosis and therefore unbi-
ased by outcome. Registry-based cohort studies have been
based on records of women hospitalised for pregnancy-
complications, therefore reﬂecting conﬁrmed diagnoses, but
did not have complete data on other important breast cancer
risk and lifestyle factors. In the Generations Study extensive
pregnancy and other breast cancer risk factor data were col-
lected and our analyses were adjusted for a wide range of
potential confounders.
In conclusion, our results suggest that preeclampsia is
associated with a decreased risk of breast cancer at premeno-
pausal ages and of HER2-enriched breast cancer. We did not
ﬁnd evidence that a history of hyperemesis was associated
with breast cancer risk overall, but there was a positive asso-
ciation with the HER2-enriched subtype.
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